ImmunoGen, Inc. Announces Development of Trastuzumab Emtansine for Early Stage HER2-Positive Breast Cancer
In its analyst event presentation, Roche reported that it intends to initiate three studies with trastuzumab emtansine for early stage HER2-positive breast cancer, assessing the compound:
- As single-agent therapy for patients with residual invasive disease following preoperative (neoadjuvant) systemic treatment;
- Used in combination with chemotherapy and pertuzumab in the adjuvant setting; and
- Used in combination with chemotherapy and pertuzumab in the neoadjuvant setting.
Roche expects to begin all three trials in 2013. Additional details on the plans reported are available on Roche's website, www.roche.com.
"Genentech and Roche have unparalleled experience in the development of
HER2-targeting antibody therapies for breast cancer," commented
Trastuzumab emtansine is currently being evaluated in three Phase III
trials for the treatment of HER2-positive metastatic breast cancer. Data
from the first of these, EMILIA, were reported in a plenary session at
ASCO earlier today and, per Roche, will form the basis of its applying
for marketing approval of the compound in the US and
Trastuzumab emtansine comprises ImmunoGen's DM1 cancer cell-killing
agent linked using the Company's method of attachment to the trastuzumab
antibody developed by
About
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including trastuzumab emtansine, including risks related to clinical
studies and regulatory submissions, their timings and results. A review
of these risks can be found in ImmunoGen's Annual Report on Form 10-K
for the fiscal year ended
For Investors:
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For
Media:
The Yates Network
Source:
News Provided by Acquire Media